New study to map Real-World use of iptacopan in rare kidney disease

This study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is to learn more about the types of patients using iptacopan and their outcomes in real-world clinics.